Personal tools
You are here: Home Consortium AstraZeneca
Document Actions

AstraZeneca

by Olivier De Bardonneche last modified 27-03-2007 22:43

AstraZeneca, Genetic Toxicology, Safety Assessment UK

COMET ASSAY and CELL ARRAY for genotoxicity testing - non-animal alternative for REACH

 

AstraZeneca logo

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. AstraZeneca make new medicines that are designed to improve the health and quality of life of patients around the world. Safety Assessment’s role is to evaluate the safety of new AstraZeneca medicines. The Genetic Toxicology Department provides data on the genetic toxicity of new compounds in Discovery; fulfills the requirements of the guidelines with respect to genotoxicity testing; produces genetic toxicity risk assessments that document the safety of candidate drugs and ensure successful registration. Tests used within the department include bacterial and mammalian cell mutation assays, cytogenetic analysis, comet assay and DNA binding assay.


Principal scientific and technical personnel

Dr Michael O’Donovan. Global Discipline Leader, Genetic Toxicology, AstraZeneca. 24 years research experience in the field of Genetic Toxicology. Dr Elizabeth Martin, Team Leader in Genetic Toxicology, AstraZeneca. 13 years research experience in the field of genotoxicity and DNA adducts. Experience in comet assay (study design, validation and use of enzymes) for 2 years. Dr Catherine Smith, Scientist in Genetic Toxicology; PhD in Molecular Toxicology. 2 years post-doctoral research in comet assay (study design, validation and use of enzymes).

Recent publications

1. Martin EA et al. Evaluation of the modified comet assay: the use of lesion specific repair endonucleases to distinguish oxidative damage from other DNA lesions. Env. Mol. Mutagen. (In press) 2. Smith CC et al. Evaluation of the formamidopyrimidine-DNA glycosylase (FPG), endonuclease III (ENDOIII) and human 8-OH-GUA glycosylase (hogg1) modifications of the comet assay in distinguishing oxidative damage from other DNA lesions. Mutagenesis. 20 (In press). 3. Smith CC et al. Formamidopyrimidine glycosylase (FPG) modification of the comet assay: Utility in distinguishing oxidative damage from other DNA lesions. Toxicol. 213 p 241, 2005. 4. Knudsen LE et al. Genotoxic damage in mine workers exposed to diesel exhaust, and the effects of glutathione transferase genotypes. Mut. Res. 583 120-132, 2005. 5. Narayanan et al. Lysis of whole blood in vitro causes DNA strand breaks in human lymphocytes. Mutagenesis. 16, 455-459, 2001.

comics.vitamib.com

COMET ASSAY and CELL ARRAY for genotoxicity testing - non-animal alternative for REACH
« September 2017 »
Su Mo Tu We Th Fr Sa
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

EUFLAG
EU funded project

pnb